Human TRAIL R3/TNFRSF10C Antibody

Catalog # Availability Size / Price Qty
MAB6302
MAB6302-SP
Human TRAIL R3/TNFRSF10C Antibody in Data
1 Image
Product Details
Citations (12)
FAQs
Supplemental Products
Reviews (1)

Human TRAIL R3/TNFRSF10C Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R1, or rhTRAIL R4 is observed.
Source
Monoclonal Mouse IgG1 Clone # 90906
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C
Met1-Ala221
Accession # O14798
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Flow Cytometry
0.25 µg/106 cells
See below
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Example

Flow Cytometry Detection of TRAIL R3/TNFRSF10C antibody in Human Blood Granulocytes antibody by Flow Cytometry. View Larger

Detection of TRAIL R3/TNFRSF10C in Human Blood Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with Mouse Anti-Human TRAIL R3/TNFRSF10C Monoclonal Antibody (Catalog # MAB6302, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B).

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAIL R3/TNFRSF10C

Human TRAIL R3, also known as DcR1 (Decoy Receptor 1), LIT, and TRID, is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity. In the new TNF superfamily nomenclature, TRAIL R3 is referred to as TNFRSF10C. TRAIL R3 has the TRAIL-binding extracellular cysteine-rich domains but lacks the intracellular signalling domain. As a result, binding of TRAIL to TRAIL R3 does not transduce an apoptosis signal. Expression of TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis. A second TRAIL decoy receptor, which binds TRAIL with high-affinity but antagonizes TRAIL-induced apoptosis, named TRAIL R4, DcR2 or TRUNDD, has also been reported. The human soluble TRAIL R3/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

References
  1. Sheridan, J.P. et al. (1997) Science 277:818.
  2. Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 3
Entrez Gene IDs
8794 (Human)
Alternate Names
Antagonist decoy receptor for TRAIL/Apo-2L; CD263 antigen; CD263; cytotoxic TRAIL receptor-3; DcR1; DCR1MGC149502; Decoy receptor 1; Decoy TRAIL receptor without death domain; LITMGC149501; Lymphocyte inhibitor of TRAIL; TNFRSF10C; TRAIL R3; TRAIL receptor 3; TRAIL receptor without an intracellular domain; TRAILR3; TRAIL-R3; TRAILR3TNF-related apoptosis-inducing ligand receptor 3; TRIDDCR1-TNFR; tumor necrosis factor receptor superfamily member 10C; tumor necrosis factor receptor superfamily, member 10c, decoy without anintracellular domain

Product Datasheets

Citations for Human TRAIL R3/TNFRSF10C Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

12 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
    Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
    Anticancer Res, 2014;34(2):729-34.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  2. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
    Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
    J Biol Chem, 2014;289(23):16576-87.
  3. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
    Cancer Gene Ther., 2012;19(9):652-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  4. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
    Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
    J. Cell. Physiol., 2010;222(2):357-64.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  5. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
    Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
    Blood, 2009;114(18):3854-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
    Oncogene, 2008;27(30):4161-71.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
    Cell Death Differ., 2008;15(4):718-729.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
    Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
    Mol. Cancer Ther., 2008;7(8):2328-38.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
    J. Cell. Biochem., 2008;104(2):595-605.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  10. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
    Authors: Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J
    J. Invest. Dermatol., 2007;127(10):2425-37.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
    Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
    Mol. Cancer Ther., 2007;6(12):3219-28.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  12. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
    Authors: Singh TR, Shankar S, Srivastava RK
    Oncogene, 2005;24(29):4609-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human TRAIL R3/TNFRSF10C Antibody

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human TRAIL R3/TNFRSF10C Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human TRAIL R3/TNFRSF10C Antibody
By Anonymous on 07/17/2018
Application: WB Sample Tested: THP-1 human acute monocytic leukemia cell line Species: Human

THP-1 cells were treated with LPS (100 mg/ml) for 24h. Total cell lysates were subjected to western blot. PVDF membrane were probed with 1mm/ml Human TRAIL R3 Antibody (MAB6302). A specific band was detected for TRAIL R3 at approximately 28 kDa. This experiment was conducted under reducing conditions.